What Affinia Therapeutics’ UPBEAT trial reveals about the next phase of inherited heart failure gene therapy
Affinia Therapeutics has cleared AFTX-201 for a Canadian BAG3 DCM trial. Read why the gene therapy’s design and risks matter now.
What Ocugen, Inc.’s OCU410ST milestone means for the race to treat inherited retinal blindness
Discover what Ocugen, Inc.’s OCU410ST milestone means for the future of inherited retinal blindness treatment and the race toward first approval.
Can AviadoBio’s thalamic delivery strategy give AVB-101 an edge in frontotemporal dementia?
AviadoBio’s AVB-101 has moved into a new ASPIRE-FTD cohort. Read what the early biomarker, safety, and strategy signals could mean next.
Can VeonGen Therapeutics validate VR-based endpoints as Stargardt trials move toward pivotal design
VG801 shows early vision gains in Stargardt disease. Find out what this means for gene therapy endpoints and regulatory pathways.
Ferring wins ADSTILADRIN label update as operational efficiency becomes a bigger oncology battleground
FDA clears faster ADSTILADRIN thawing for bladder cancer care. Read why this workflow update could matter for NMIBC adoption and treatment strategy.
One-time gene therapy approach from Ocugen gains traction in dry AMD pipeline race
Ocugen reports positive phase 2 data for OCU410 in geographic atrophy. Learn what this means for retinal care, regulation, and future gene therapy adoption.
What Celosia Therapeutics’ Phase 1b CTx1000 trial could reveal about TDP-43 targeting in ALS
Celosia Therapeutics has dosed the first ALS patient with CTx1000. Read why this TDP-43 gene therapy trial could reshape the ALS pipeline.
How Sensorion’s SENS-501 data could reshape gene therapy for congenital hearing loss treatment
Sensorion reports promising gene therapy data for congenital deafness. Discover what it means for hearing loss treatment and future clinical breakthroughs.
Gene therapy gains ground in bladder cancer as NCCN strengthens Ferring Pharmaceuticals’ ADSTILADRIN recommendation
ADSTILADRIN gains NCCN upgrade in bladder cancer. Discover what this means for gene therapy adoption, clinical use, and future NMIBC treatment trends.
Cathy Tie’s Origin Genomics targets germline gene correction under US IRB oversight
Origin Genomics launches in New York to advance germline gene correction and MRT under IRB oversight. Analyse what it means for US gene editing regulation.